Back to results
US 12,280,102 B2Granted
Alphavirus replicon encoding chimeric SARS-CoV-2 receptor binding domains
AssigneeVLP Therapeutics, LLC
InventorsWataru Akahata, Jonathan F. Smith, Ryuji Ueno
Life of this patent
Estimating the term…
Abstract
Provided herein is an isolated polynucleotide, which encodes alphavirus non-structural proteins nsp1, nsp2, nsp3 and nsp4 and a polypeptide comprising a coronavirus protein fused to a signal sequence and/or transmembrane domain. The coronavirus protein may be the receptor binding domain of the S1 subunit of coronavirus spike (S) protein. The polynucleotide such as RNA is useful for as a vaccine against coronavirus infection, especially, COVID-19 infection.
Claims16
An isolated polynucleotide, which encodes alphavirus non-structural proteins nsP1, nsP2, nsP3, and nsP4 and
- a polypeptide comprising a receptor binding domain (RBD) of an S1 subunit in a spike protein of a SARS-CoV2 fused to a transmembrane domain and optionally to a signal sequence,
- wherein the alphavirus is Venezuelan Equine Encephalitis Virus or Chikungunya virus, and
- wherein the transmembrane domain is heterologous to the SARS-CoV-2.
Dependencies are inferred from the claim text.